Please assess the completion status of the following clinical trial:

Trial Title: Trial of NanoPac Focal Therapy for Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age;~* Histopathologically proven adenocarcinoma of the prostate:~  * Localized cancer;~ * Subjects with tumors classified as \<T3 per TNM classification, Gleason score≥ 6;~* Prostate tumor must be able to be visualized on mpMRI;~* Already considered to be candidate for radical prostatectomy;~* Considered appropriate for treatment with paclitaxel therapy;~* Laboratory requirements:~  * WBC \>2500/mm3~ * Neutrophil \>1500/mm3~ * Hemoglobin \>10 mg/dL~ * Platelet \>100,000/ mm3~ * AST and ALT \<2.5 x ULN~ * Total bilirubin \<1.5 x ULN~ * Calculated creatinine clearance ≥ 30 ml/min~ * Normal PT/INR and PTT;~* ECOG of 0 or 1;~* International Prostate Symptom Score (I-PSS) less than or equal to 20;~* If sexually active, willing to use double condoms from time of NanoPac injection until prostatectomy;~* Agree to all study procedures and provide signed informed consent;~Exclusion Criteria:~* Evidence of locally advanced or metastatic disease;~* Prostate size ≥ 50 cc;~* Prior prostatectomy, including surgery for any benign condition (such as TURP);~* Anticipated use of concomitant chemotherapy (other than the protocol specified agents), immunotherapy, or systemic use of hormonal therapy (such as GnRH analogs, antiandrogens, androgen receptor inhibitors, and 5-α reductase inhibitors) while on study prior to surgery;~* Treatment with a prior investigational medication within 30 days of first dose of study agent;~* Any previous local treatment of the prostate (e.g. radiation, HIFU, cryotherapy, Focal Irreversible Electroporation, Photodynamic Therapy, Laser Induced Thermometry);~* Any other condition (e.g., psychiatric disorder) that, in the opinion of the Investigator, may interfere with the subject's ability to comply with the study requirements or visit schedule;~* Known sensitivity to any of the study agent components;~* History of prior malignancy that has not been in remission for \>5 years, with the exception of basal cell or squamous cell carcinoma.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NanoPac (Type: EXPERIMENTAL): Direct injection of NanoPac at 15 mg/mL at a volume not to exceed the volume of the prostate cancer lesion (no more than 10% of total prostate volume). NanoPac will be administered on up to three occasions, with at least 28 days between each dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).